Product
Supplier
Encyclopedia
Inquiry
Home > Encyclopedia > CH5132799

CH5132799

CH5132799 structure

CH5132799 

structure
  • CAS No:

    1007207-67-1

  • Formula:

    C15H19N7O3S

  • Chemical Name:

    CH5132799

  • Synonyms:

    CH5132799;CH5132799,5-(7-(Methylsulfonyl)-2-Morpholino-6,7-dihydro-5H-pyrrolo[2,3-d]pyriMidin-4-yl)pyriMidin-2-aMine;[5-[7-Methylsulfonyl-2-(morpholin-4-yl)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl]pyrimidin-2-yl]amine;5-(7-(Methylsulfonyl)-2-Morpholino-6,7-dihydro-5H-pyrrolo[2,3-d]pyriMidin-4-yl)pyriMidin-2-aMine;[5-[7-Methylsulfonyl-2-(morpholin-4-yl)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl]pyrimidin-2-yl]amineCH5132799;5-(7-(Methylsulfonyl)-2-morpholino-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrimidin-2-ami

  • Categories:

    Biochemical Engineering  >  Inhibitors

Description

CH5132799 is a selective class I PI3K inhibitor. CH5132799 inhibits class I PI3Ks, particularly PI3Kα, with an IC50 of 14 nM.


CH5132799 has been used in trials studying the treatment of Solid Tumors.|PI3K-alpha Inhibitor MEN1611 is an orally bioavailable inhibitor of the class I phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) catalytic subunit alpha (PIK3CA), with potential antineoplastic activity. PI3K alpha inhibitor MEN1611 selectively binds to and inhibits PIK3CA and its mutated forms in the PI3K/Akt (protein kinase B)/mammalian target of rapamycin (mTOR) pathway. This results in both apoptosis and growth inhibition in PIK3CA-expressing tumor cells. By specifically targeting PIK3CA, this agent may be more efficacious and less toxic than pan-PI3K inhibitors. In addition, MEN1611 also targets mutated forms of PI3K gamma (PI3Kg). MEN1611 may stimulate the immune system to restore CD8+ T-cell activation and cytotoxicity. Dysregulation of the PI3K/Akt/mTOR pathway is often found in solid tumors and results in the promotion of tumor cell growth, survival, and resistance to chemo- and radio-therapy. PIK3CA, one of the most frequently mutated oncogenes, encodes the p110-alpha catalytic subunit of the class I PI3K. In most solid tumors, the activation of the PI3K pathway is induced by mutations of PIK3CA.

CH5132799 Basic Attributes

377.42146

377.127014

JCL936W835

DTXSID40678540

C158603

Characteristics

136

-0.6

1.58

751.1±70.0 °C(Predicted)

408.1±35.7 °C

1.706

Drug Information

CH 5132799

CH5132799 Use and Manufacturing

To a DMF solution (550 ml) of 4-chloro-7-methanesulfonyl-2-morpholin-4-yl-6, 7-dihydro-5H-pyrrolo[2, 3-d]pyrimidine (57.9 g, 181.6 mmol) prepared according to Example 4, Step A, 2-amino-5-(4, 4, 5, 5-tetramethyl-1, 3, 2-dioxaborolan-2-yl)pyrimidine (48.2 g, 218.0 mmol), potassium phosphate (42.4 g, 199.8 mmol) and water (30 ml) were added, and degassed under a nitrogen atpmosphere.

Computed Properties

Molecular Weight:377.4
XLogP3:-0.6
Hydrogen Bond Donor Count:1
Hydrogen Bond Acceptor Count:10
Rotatable Bond Count:3
Exact Mass:377.12700867
Monoisotopic Mass:377.12700867
Topological Polar Surface Area:136
Heavy Atom Count:26
Complexity:587
Covalently-Bonded Unit Count:1
Compound Is Canonicalized:Yes

Recommended Suppliers of CH5132799

Scan the QR Code to Share

Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.